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ABSTRACT
Background    The neutrophil lymphocyte ratio (NLR) 
has been proposed to be a surrogate marker of inflam-
mation and immunological status and to have prognostic 
value in various malignancies. This study was conduct-
ed to clarify the prognostic significance of preoperative 
NLR in hepatocellular carcinoma (HCC). 
Methods    We enrolled 135 patients with histologically-
proven HCC who underwent initial curative hepatec-
tomy. Based on the median NLR values, patients were 
divided into: NLR ≥ 2.0 (NLR-high, n = 69) and NLR < 
2.0 (NLR-low, n = 66). 
Results    In univariate analysis, the 5-year overall sur-
vival (OS) rates were 59.8 % ± 6.7% and 75.6% ± 6.5% (P 
= 0.028) in the NLR-high and NLR-low groups, respec-
tively. Furthermore, the 5-year disease specific survival 
rates were 68.6% ± 6.7%, and 81.2 ± 6.4% (P = 0.048) in 
the NLR-high and NLR-low groups, respectively. 
Conclusion    Our results showed that high NLR was 
an independent predictor for OS in hepatectomy-treated 
HCC, suggesting that NLR may be a novel prognostic 
biomarker for HCC. On the other hand, NLR also has 
a limitation to predict postoperative prognosis of HCC 
patients by itself.
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Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer and the third-leading cause of cancer-related 
deaths worldwide.1 Hepatic resection is considered as a 
curative treatment for HCC.2 However, the 5-year overall 
survival rate after curative resection for HCC patients 
has been reported to be 40%–50%,3 which remains un-
satisfactory. Therefore, to select patients with poor prog-
noses who should not be indicated for invasive hepatic 
resection, the development of pre-operative prognostic 
factors for HCC patients is urgently needed.
 Several prognostic factors have been identified 
that predict long-term outcomes of HCC patients.4-10 
Increasing evidence has supported that the involvement 
of systemic inflammation and immunological status 
in HCC patients are closely associated with cancer 
progression.11, 12 Recently, the neutrophil to lymphocyte 
ratio (NLR) was proposed to be a surrogate marker 
of inflammation and immunological status, as it was 
reported to render prognostic value in various malig-
nancies,13–16 including HCC, which is closely associ-
ated with hepatic inflammation.17–20 Moreover, NLR 
is supposed to be associated with malignant potential 
and host-immunity, because a number of reports have 
indicated that neutrophils promote tumor angiogenesis 
and cancer metastasis, and that lymphocytes have antitu-
mor activity with their cytotoxic function.21, 22 Therefore, 
NLR could be a promising candidate for identifying 
HCC patients with poor prognosis who should avoid in-
vasive liver resection. Thus far, few studies have demon-
strated associations between preoperative NLR and 
the prognosis of HCC patients who underwent curative 
surgery. Thus, this study was conducted to clarify the 
prognostic significance of preoperative NLR in patients 
with HCC.
MATERIALS AND METHODS
Patients
This study enrolled 135 patients with histologically-prov-
en HCC who underwent initial and curative hepatectomy 
at Tottori University Hospital between 2004 and 2013. 
This was a retrospective study, thus clinicopathological 
data was collected from medical records. Medical re-
cords were reviewed after approval by the Institutional 
Review Board (IRB) of our institution in accordance 
with the ethical standards laid down in the 1964 
Declaration of Helsinki and its later amendments (IRB 
approval number: 17A135). Pathological findings were 
classified according to the 5th. edition of The General 
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Rules for the Clinical and Pathological Study of Primary 
Liver Cancer.23 After surgery, patients were routinely 
followed-up for disease recurrence with measurements 
of serum tumor markers such as alpha-fetoprotein (AFP) 
and protein induced by vitamin K absence or antagonist 
II (PIVKA II), and diagnostic images including ultraso-
nography, computed tomography, or magnetic resonance 
imaging every 6 months. Information on the cause of 
death and type of recurrence were obtained from medi-
cal records.
 Pre-operative NLR was defined as the absolute neu-
trophil count divided by the absolute lymphocyte count 
obtained from blood tests within a week before surgery. 
Overall survival (OS) was defined as the interval be-
tween the date of surgery and the date of death from any 
causes or the last date when the patient was confirmed to 
be alive. Recurrence-free survival (RFS) was defined as 
the interval between the date of surgery and the date of 
recurrence, the date of death from any cause, or the last 
date when the patient was last known to be alive.
Statistical analysis
For statistical analyses, GraphPad Prism (GraphPad 
Software Inc., La Jolla, CA) and SPSS version 25 (IBM, 
Armonk, NY) were used. OS and RFS rates were calcu-
lated according to the Kaplan–Meier method and com-
pared using the log-rank test. Critical factors identified 
as unity variability by P < 0.05 were further investigated 
by the multivariate Cox proportional hazards model to 
determine independent and significant factors for surviv-
al. The hazard ratio (HR) and 95% confidence interval 
(CI) were calculated for all estimates. The cutoff value 
for NLR in this study was the median value to divide the 
cohort into two groups without any bias from statistical 
intervention. P < 0.05 was considered significant. All 
continuous values are presented as mean ± standard 
deviation. Statistical analyses were conducted using the 
chi-squared test for categorical variables and Welch’s 
two-sample t test for continuous variables, with the 
exception of categorical variables containing factors < 5, 
which were analyzed using Fisher’s exact test.
RESULTS
The median follow-up period of 135 HCC patients was 
54.7 ± 33.6 months. Based on the median NLR value, 
patients were divided as follows: NLR ≥ 2.0 (NLR-high, 
n = 69), NLR < 2.0 (NLR-low, n = 66). Table 1 shows 
the correlation of clinicopathological factors between 
the NLR-high and the NLR-low groups. Pearson’s chi-
square test between the two groups showed that only 
vascular invasion (P = 0.021) was significantly more 
common in the NLR-low group (Table 1). There were no 
significant differences between the two groups in other 
clinicopathological factors.
 In the univariate analysis using the Kaplan-Meier 
method, the 5-year OS rates were 59.8% ± 6.7%, and 
75.6% ± 6.5% (P = 0.028) in the NLR-high and NLR-
low groups, respectively (Fig. 1A). Furthermore, the 
5-year disease specific survival rates were 68.6% ± 6.7%, 
and 81.2% ± 6.4% (P = 0.048) in the NLR-high and 
NLR-low groups, respectively (Fig. 1B). Multivariate 
analysis was performed to determine whether preop-
erative NLR was an independent predictor of OS and 
confirmed that the NLR-high group (HR: 2.221, 95% 
Table 1. Correlations of clinicopathological factors between the NLR-high and NLR-low groups
NLR < 2.0 NLR ≥ 2.0
n = 66 n = 69
P value
Age (y) < 65/65 ≤ 16/50 17/52 0.957
Gender Male/Female 58/8 55/14 0.199
HBsAg Positive/Negative 23/43 26/43 0.732
HCV Positive/Negative 23/43 21/48 0.584
DM Yes/No 23/43 23/46 0.853
AFP (ng/mL) < 10/10 ≤ 29/37 38/26 0.13
Operation duration (min) < 360/360 ≤ 27/39 27/41 0.746
Extent of resection Miner/Major 51/15 48/21 0.233
Number Single/Multiple 50/16 57/12 0.326
Tumor size (cm) < 5.0/5.0 ≤ 48/18 47/22 0.558
Histotype Well, Moderately/Poor 61/5 64/5 0.535
vp (–)/(+) 26/40 37/32 0.021
Stage Ⅰ/Ⅱ- 38/28 31/38 0.142
Liver cirrhosis Yes/No 24/42 21/47 0.625
AFP, alpha-fetoprotein; DM, diabetes mellitus; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; NLR, 
neutrophil to lymphocyte ratio; vp, portal vein invasion; y, years.
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Table 2. Univariate and multivariate analyses of prognostic factors of overall survival for HCC patients
Univariate analysis Multivariate analysis
HR 95% CI P value HR 95% CI P value
Age (y) < 65/65 ≤ 1.324 0.679–2.582 0.411
Gender Male/Female 0.723 0.350–1.494 0.381
HBsAg Positive/Negative 0.689 0.490–1.602 0.689
HCV Positive/Negative 1.659 0.953–2.890 0.074
DM Yes/No 0.764 0.417–1.401 0.384
NLR < 2/2 ≤ 1.872 1.061–3.301 0.03 2.221 1.113–4.431 0.024
AFP (ng/mL) < 10/10 ≤ 2.09 1.134–3.851 0.018 2.481 1.226–5.020 0.011
Operation duration (time) < 360/360 ≤ 1.367 0.746–2.503 0.312
Extent of resection Miner/Major 1.023 0.553–1.895 0.941
Number Single/Multiple 1.84 1.004–3.371 0.048 4.785 1.974–11.60 0.001
Tumor size (cm) < 5.0/5.0 ≤ 1.986 1.134–3.477 0.016 1.951 1.012–3.760 0.046
Histotype Well, Moderately/Poor 7.294 2.954–18.01 < 0.001 3.36 1.060–10.64 0.039
vp (–)/(+) 2.238 1.268–3.949 0.005 3.321 1.122–9.832 0.030
Stage Ⅰ/Ⅱ- 2.019 1.114–3.659 0.021 0.369 0.106–1.291 0.119
Liver cirrhosis Yes/No 1.402 0.754–2.607 0.286
AFP, alpha-fetoprotein; CI, confi dence interval; DM, diabetes mellitus; HBsAg, hepatitis B surface antigen; HCC, 
hepatocellular carcinoma; HCV, hepatitis C virus; HR, hazard ratio; NLR, neutrophil to lymphocyte ratio; vp, portal 
vein invasion; y, years.
CI: 1.113–4.431, P = 0.024), the high AFP value (HR: 
2.481, 95% CI: 1.226–5.020, P = 0.011), multiple tumors 
(HR: 4.785, 95% CI: 1.974–11.60, P = 0.001), large 
tumors (HR: 1.951, 95% CI: 1.012–3.760, P = 0.046), 
poor differentiation (HR: 3.360, 95% CI: 1.060–10.64, 
P = 0.039), and vascular invasion (HR: 3.321, 95% CI: 
1.122–9.832, P = 0.030) were independent prognostic 
factors (Table 2). On the contrary, there was no signifi -
cant association between NLR value and RFS (Fig. 2). 
We suspect that this discrepancy is from the difference 
between survival periods after disease recurrence. To 
confi rm this, we analyzed survival durations after recur-
rence among patients whose disease had recurred during 
follow-up (n = 78). The 5-year survival rates after recur-
rence were significantly lower in the NLR-high group 
than in the NLR-low group among relapsed patients (22.8 
± 8.7 % and 59.4 ± 9.3 %, respectively, P = 0.004; Fig. 
3A). We also confi rmed that the OS of patients who had 
The overall survival according to 
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Fig. 1. Survival curves of this cohort according to preoperative NLR. (A) Overall survival; the 5-year survival rates were 59.8% ± 6.7% 
and 75.6% ± 6.5% in the NLR-high and NLR-low groups, respectively. (B) The disease-specifi c survival and the 5-year survival rates 
were 68.6% ± 6.7% and 81.2% ± 6.4% in the NLR-high and NLR-low groups, respectively. NLR, neutrophil to lymphocyte ratio.
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Fig. 2. Recurrence-free survival according to NLR; the 5-year 
recurrence-free survival rates were 52.8% ± 6.8% and 54.5% ± 
7.0% in the NLR-high and NLR-low groups, respectively. NLR, 
neutrophil to lymphocyte ratio.
Fig. 3. Survival curves of relapsed and non-relapsed patients. (A) Survival rates after recurrence (n = 78) according to NLR values; the 
5-year survival rates after recurrence were 59.4% ± 9.3% and 22.8% ± 8.7% in the NLR-high, and NLR-low groups, respectively. (B) 
Survival rates of patients without recurrence (n = 56) according to NLR value. No signifi cant difference was seen among patients who 
had not recurred during the follow-up period. NLR, neutrophil to lymphocyte ratio.
no recurrence during follow-up showed no difference 
between the NLR-high and NLR-low groups (P = 0.657, 
Fig. 3B).
DISCUSSION
NLR has been reported to be useful as a prognostic 
predictor for patients with colorectal cancer,13 gastric 
cancer,14 and lung cancer.15 In this study, we evaluated 
the relationships between preoperative NLR, clinico-
pathological features and long-term outcomes in HCC 
patients that had undergone curative resection. Our 
results clearly showed that preoperative high NLR was a 
surrogate marker of advanced HCC and an independent 
prognostic factor for survival after complete resection. 
These results were consistent with those of previous 
reports.17, 24, 25  However, we also revealed that NLR pre-
dicts limited clinical outcomes but does not predict HCC 
recurrence after curative resection.
 The components of NLR are lymphocyte and neu-
trophil counts. Neutrophils, a component of NLR, are 
related to infl ammation caused from tumors.26 Indeed, 
infl ammatory responses are closely related to stages of 
tumor development, including initiation, progression, 
malignant conversion, invasion, and metastasis.11 
Moreover, the circulating neutrophils induced from 
inflammation are known to produce chemokines, and 
cytokines, such as tumor necrosis factor, interleukin-1, 
interleukin-6, and vascular endothelial growth factor, 
which promote tumor proliferation, angiogenesis, inva-
sion, and metastasis.20, 27, 28 Conversely, lymphocytes, the 
other component of NLR, are related to host-immunity 
and suppress cancer progression by producing cytotoxic 
cell death ligands and cytokines that inhibit tumor cell 
proliferation and metastasis.25, 29, 30 Therefore, a high 
NLR, which is calculated from results of both decreased 
lymphocyte count and an increased neutrophil count, may 
reflect highly malignant HCC and poor host-immunity 
against HCC.  
 This study revealed that NLR reflects patient 
immunity in addition to tumor malignancy. First, we 
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confirmed that NLR reflects tumor malignancy, because 
NLR was well associated with tumor size and portal 
vein invasion. Second, to confirm that NLR reflects 
host-immunity, we used multivariate analysis and con-
cluded that high NLR is a prognostic factor independent 
from tumor malignancy, such as high AFP value, multi-
ple tumors, and poor differentiation, which are reported 
to be risk factors after liver resection from previous 
studies.5, 31 Taken together, these results suggested that 
NLR is informative for predicting patients’ oncological 
outcomes before surgery. 
 However, patients with higher NLR correlated with 
lower OS in this study, but there was no statistically sig-
nificant difference for RFS between the NLR-high and 
NLR-low groups. Consistently, several previous studies 
have shown no or weak associations between NLR and 
RFS.32 Since OS is affected by treatments for recurrent 
HCC and RFS is not, these results imply that high-NLR 
indicate patients with a low tolerance for treatments 
after recurrence. At the same time, because treatments 
for recurrent HCC depend on patients’ and tumor status 
and vary wide range, the predictive value of the NLR 
for patients at surgical stage may be limited. Indeed, 
we confirmed that patients in the NLR-high group had 
shorter survival after tumor relapse than those in the 
NLR-low group. On the contrary, the OS of patients 
without recurrence showed no significant difference 
between the NLR-high and NLR-low groups, suggesting 
that NLR purely predicted oncological outcomes. Thus, 
it is purely limited to use as a prognostic prediction after 
first resection. In other words, patients with high NLR 
have an equal potential to survive as those with low 
NLR when HCC is curatively resected and not recurrent.
 We reviewed past literature evaluating preoperative 
NLR for cases after HCC resection in Pubmed (Table 3). 
There were two values that might affect the predictive 
value of the NLR: One was the cutoff value of NLR. In 
this study, we almost equally divided this cohort into 
two groups without determining an optimal cutoff value 
for NLR because there is no universal consensus regard-
ing the cut-off level of NLR for predicting the prognosis 
of HCC patients.33, 34 The range of these values were 
wide from 1.2825 to 2.81.35 Thus, this made conclusions 
slight differ and the optimal NLR values for predicting 
patients’ prognoses should be determined for routine 
clinical usage by a large-scale study. The other notable 
value was the survival period of patients. The 5-year 
RFS in this study was tended to be better than those of 
past studies. A possible reason of better prognosis in this 
study was that a certain number of early HCC patients 
were included in our cohort, resulting in canceling out 
predictive effect of NLR on HCC recurrence. There 
are also several limitation to be mentioned. This survey 
was a retrospective study from a single institution with a 
relatively small sample size.
 In conclusion, our results showed that high NLR 
was an independent predictor of OS, suggesting that 
NLR may be a novel prognostic biomarker for HCC. 
Because patients with high NLR are supposed to be less 
tolerant of treatments for recurrent HCC than those with 
low NLR, patients with preoperative high NLR should 
be carefully monitored for invasive hepatectomy because 
they are less tolerant of treatments after recurrence. On 
the other hand, because NLR is supposed to be associ-
ated with treatment of recurrence after resection as well 
as malignancy of HCC, the predictive value of NLR 
depends on not only surgical procedure, but also the 
other unguessed factors derived from multidisciplinary 
therapy. From this aspect, NLR also has a limitation 
to predict postoperative prognosis of HCC patients by 
itself.
The authors declare no conflict of interest.
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